<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE- candesartan cilexetil and hydrochlorothiazide tablet </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_fecbe2b3-2c5d-4086-88db-f3098fbd9e89"></a><a name="section-1"></a><p></p>
<h1>WARNING: FETAL TOXICITY</h1>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">When pregnancy is detected, discontinue candesartan cilexetil and hydrochlorothiazide tablets as soon as possible</span>.</dd>
<dt>•</dt>
<dd><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. See <a href="#ID_9dbf1829-b1ad-46a6-bce7-fad62a4a892a">WARNINGS: Fetal Toxicity</a>.</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_6d851c25-db9f-4909-b638-f03c3d049b07"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Candesartan cilexetil and hydrochlorothiazide tablets combine an angiotensin II receptor (type AT<span class="Sub">1</span>) antagonist and a diuretic, hydrochlorothiazide.</p>
<p> Candesartan cilexetil, a nonpeptide, is chemically described as (±)2-Ethoxy-1-[[2’-(1<span class="Italics">H</span>-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-1<span class="Italics">H</span>-benzimidazole-7-carboxylic acid-1-[[(Cyclohexyloxy)carbonyl]oxy]ethyl ester.</p>
<p> Its molecular formula is C<span class="Sub">33</span>H<span class="Sub">34</span>N<span class="Sub">6</span>O<span class="Sub">6</span>, and its structural formula is </p>
<div class="Figure">
<a name="id1984121122"></a><img alt="Candesartan Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d&amp;name=image-01.jpg">
</div>
<p> Candesartan cilexetil, USP is a white to off-white powder with a molecular weight of 610.66. It is practically insoluble in water, soluble in methylene chloride and slightly soluble in methanol. Candesartan cilexetil is a racemic mixture containing one chiral center at the cyclohexyloxycarbonyloxy ethyl ester group. Following oral administration, candesartan cilexetil undergoes hydrolysis at the ester link to form the active drug, candesartan, which is achiral.</p>
<p> Hydrochlorothiazide is 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-,1,1-dioxide. Its molecular formula is C<span class="Sub">7</span>H<span class="Sub">8</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2 </span>and its structural formula is</p>
<div class="Figure">
<a name="id-495727847"></a><img alt="Hydrochlorothiazide Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d&amp;name=image-02.jpg">
</div>
<p> Hydrochlorothiazide, USP is a white, or practically white, practically odorless crystalline powder with a molecular weight of 297.7, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.</p>
<p> Candesartan cilexetil and hydrochlorothiazide tablets are available for oral administration in three tablet strengths of candesartan cilexetil and hydrochlorothiazide.</p>
<p>Candesartan cilexetil and hydrochlorothiazide tablets contain 16 mg or 32 mg of candesartan cilexetil, USP and 12.5 mg or 25 mg of hydrochlorothiazide, USP providing for the following available combinations: 16 mg/12.5 mg, 32 mg/12.5 mg or 32 mg/25 mg. The inactive ingredients of the tablets are carboxymethylcellulose calcium, corn starch, glyceryl stearate, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate and yellow iron oxide. The 16 mg/12.5 mg tablet and 32 mg/25 mg tablet also contain red iron oxide as a colorant.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_0b90b67a-a584-4b5f-9630-e1650787a6c9"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_ab90f8ce-1d9a-44b4-bff9-ce778e92b9b9"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<span class="Sub">1</span> receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathways for angiotensin II synthesis.</p>
<p> There is also an AT<span class="Sub">2</span> receptor found in many tissues, but AT<span class="Sub">2</span> is not known to be associated with cardiovascular homeostasis. Candesartan has much greater affinity (&gt; 10,000-fold) for the AT<span class="Sub">1</span> receptor than for the AT<span class="Sub">2</span> receptor.</p>
<p> Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because candesartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Candesartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p>
<p> Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of candesartan on blood pressure.</p>
<p> Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.</p>
<p> The mechanism of the antihypertensive effect of thiazides is unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_d0a2fe46-00d3-413c-833a-070bb17163b2"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d10cc490-273c-475f-93ad-e3a605af9b22"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">General</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c8713d9a-1bbe-4b30-a2e5-6fd5029abdcd"></a><a name="section-2.2.1.1"></a><p></p>
<h4>Candesartan Cilexetil</h4>
<p class="First">Candesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from the gastrointestinal tract to candesartan, a selective AT<span class="Sub">1</span> subtype angiotensin II receptor antagonist. Candesartan is mainly excreted unchanged in urine and feces (via bile). It undergoes minor hepatic metabolism by O-deethylation to an inactive metabolite. The elimination half-life of candesartan is approximately 9 hours. After single and repeated administration, the pharmacokinetics of candesartan are linear for oral doses up to 32 mg of candesartan cilexetil. Candesartan and its inactive metabolite do not accumulate in serum upon repeated once-daily dosing.</p>
<p> Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%. After tablet ingestion, the peak serum concentration (C<span class="Sub">max</span>) is reached after 3 to 4 hours. Food with a high fat content does not affect the bioavailability of candesartan after candesartan cilexetil administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a039d9a5-2c2c-4eae-928c-70406a1be41c"></a><a name="section-2.2.1.2"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_78f87524-2c83-48bd-ae4c-f72252aa184f"></a><a name="section-2.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Metabolism and Excretion</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8ee8f040-3573-47b2-9a2e-17181043f46f"></a><a name="section-2.2.2.1"></a><p></p>
<h4>Candesartan Cilexetil</h4>
<p class="First">Total plasma clearance of candesartan is 0.37 mL/min/kg, with a renal clearance of 0.19 mL/min/kg. When candesartan is administered orally, about 26% of the dose is excreted unchanged in urine. Following an oral dose of <span class="Sup">14</span>C-labeled candesartan cilexetil, approximately 33% of radioactivity is recovered in urine and approximately 67% in feces. Following an intravenous dose of <span class="Sup">14</span>C-labeled candesartan, approximately 59% of radioactivity is recovered in urine and approximately 36% in feces. Biliary excretion contributes to the elimination of candesartan.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c6494b8b-436b-4a42-baec-149be73c8c83"></a><a name="section-2.2.2.2"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. At least 61% of the oral dose is eliminated unchanged within 24 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3797f3ba-6c63-4fde-b0b0-5fcc502be54c"></a><a name="section-2.2.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Distribution</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5ca0817c-f6db-49f2-b728-7d0b5f87a574"></a><a name="section-2.2.3.1"></a><p></p>
<h4>Candesartan Cilexetil</h4>
<p class="First">The volume of distribution of candesartan is 0.13 L/kg. Candesartan is highly bound to plasma proteins (&gt; 99%) and does not penetrate red blood cells. The protein binding is constant at candesartan plasma concentrations well above the range achieved with recommended doses. In rats, it has been demonstrated that candesartan crosses the blood-brain barrier poorly, if at all. It has also been demonstrated in rats that candesartan passes across the placental barrier and is distributed in the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3fa76c8f-8364-42d7-afe9-cf60951e168b"></a><a name="section-2.2.3.2"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a2ef10d5-93b6-47b9-acc8-8e979d61a330"></a><a name="section-2.2.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Special Populations</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_44fd82b5-1e76-4f3e-8494-64d7b3c056d2"></a><a name="section-2.2.4.1"></a><p></p>
<h4>Pediatric</h4>
<p class="First">The pharmacokinetics of candesartan cilexetil have not been investigated in patients &lt; 18 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e2a0e493-2ac8-4651-b0ba-ae67294c436d"></a><a name="section-2.2.4.2"></a><p></p>
<h4>Geriatric</h4>
<p class="First">The pharmacokinetics of candesartan have been studied in the elderly (≥ 65 years). The plasma concentration of candesartan was higher in the elderly (C<span class="Sub">max</span> was approximately 50% higher, and AUC was approximately 80% higher) compared to younger subjects administered the same dose. The pharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite did not accumulate in the serum of these subjects upon repeated, once-daily administration. No initial dosage adjustment is necessary. (See <a href="#i4i_dosage_admin_id_2f004b2b-87aa-47c0-ab9c-9e657e0ceb4f">DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_aa2586cf-927d-4df2-b76d-d8e4ff8f53eb"></a><a name="section-2.2.4.3"></a><p></p>
<h4>Gender</h4>
<p class="First">There is no difference in the pharmacokinetics of candesartan between male and female subjects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_39006eb7-c45c-461b-9367-ce4bb2f90ef6"></a><a name="section-2.2.4.4"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h4>
<p class="First">In hypertensive patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, serum concentrations of candesartan were elevated. After repeated dosing, the AUC and C<span class="Sub">max</span> were approximately doubled in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt; 30 mL/min/1.73m<span class="Sup">2</span>) compared to patients with normal kidney function. The pharmacokinetics of candesartan in hypertensive patients undergoing hemodialysis are similar to those in hypertensive patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Candesartan cannot be removed by hemodialysis.</p>
<p>Thiazide diuretics are eliminated by the kidney, with a terminal half-life of 5 to 15 hours. In a study of patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (mean creatinine clearance of 19 mL/min), the half-life of hydrochlorothiazide elimination was lengthened to 21 hours. (See <a href="#i4i_dosage_admin_id_2f004b2b-87aa-47c0-ab9c-9e657e0ceb4f">DOSAGE AND ADMINISTRATION</a>.)</p>
<p>Safety and effectiveness of candesartan cilexetil and hydrochlorothiazide in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCL ≤ 30 ml/min) have not been established. No dose adjustment is required in patients with mild CrCL (60 to 90 ml/min) or moderate (CrCL 30 to 60 ml/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_38c7f1c2-354a-4c00-9e42-5d241d347fd0"></a><a name="section-2.2.4.5"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h4>
<p class="First">The pharmacokinetics of candesartan were compared in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> to matched healthy volunteers following a single dose of 16 mg candesartan cilexetil. The AUC for candesartan in patients with mild and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> was increased 30% and 145% respectively. The C<span class="Sub">max</span> for candesartan was increased 56% and 73% respectively. The pharmacokinetics of candesartan in severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been studied. No dose adjustment is recommended for patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, candesartan cilexetil and hydrochlorothiazide is not recommended for initiation because the appropriate starting dose, 8 mg, cannot be given. (See <a href="#i4i_dosage_admin_id_2f004b2b-87aa-47c0-ab9c-9e657e0ceb4f">DOSAGE AND ADMINISTRATION</a>.)</p>
<p>Monitor patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_6fe8e8f5-225d-41e4-b608-a8ef57fd0d3d"></a><a name="section-2.3"></a><p></p>
<h2>Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9f5d521a-4ca9-407e-a9b5-00bce163e6d6"></a><a name="section-2.3.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Candesartan Cilexetil</span></span></h3>
<p class="First">Candesartan inhibits the pressor effects of angiotensin II infusion in a dose-dependent manner. After one week of once-daily dosing with 8 mg of candesartan cilexetil, the pressor effect was inhibited by approximately 90% at peak with approximately 50% inhibition persisting for 24 hours.</p>
<p> Plasma concentrations of angiotensin I and angiotensin II, and plasma renin activity (PRA), increased in a dose-dependent manner after single and repeated administration of candesartan cilexetil to healthy subjects and hypertensive patients. ACE activity was not altered in healthy subjects after repeated candesartan cilexetil administration. The once-daily administration of up to 16 mg of candesartan cilexetil to healthy subjects did not influence plasma aldosterone concentrations, but a decrease in the plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was administered to hypertensive patients. In spite of the effect of candesartan cilexetil on aldosterone secretion, very little effect on serum potassium was observed.</p>
<p> In multiple-dose studies with hypertensive patients, there were no clinically significant changes in metabolic function including serum levels of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides, glucose, or uric acid. In a 12-week study of 161 patients with non-insulin-dependent (type 2) <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, there was no change in the level of HbA<span class="Sub">1c</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_97da7623-abc0-4c33-8932-77bb739e77b5"></a><a name="section-2.3.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Hydrochlorothiazide</span></span></h3>
<p class="First">After oral administration of hydrochlorothiazide, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6ba59317-4e5e-49ac-99e7-c19d0e288282"></a><a name="section-2.4"></a><p></p>
<h2>Clinical Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0d365393-82b9-470f-9ac5-1343176bb8b2"></a><a name="section-2.4.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Candesartan Cilexetil and Hydrochlorothiazide</span></span></h3>
<p class="First">Of 12 controlled clinical trials involving 4,588 patients, five were double-blind, placebo-controlled and evaluated the antihypertensive effects of single entities vs. the combination. These five trials, of 8 to 12 weeks duration, randomized 3,037 hypertensive patients. Doses ranged from 2 mg to 32 mg candesartan cilexetil and from 6.25 mg to 25 mg hydrochlorothiazide administered once daily in various combinations.</p>
<p>The combination of candesartan cilexetil and hydrochlorothiazide resulted in placebo-adjusted decreases in sitting systolic and diastolic blood pressures of 14 to 18/8 to 11 mm Hg at doses of 16 mg/12.5 mg and 32 mg/12.5 mg. The combination of candesartan cilexetil and hydrochlorothiazide 32 mg/25 mg resulted in placebo-adjusted decreases in sitting systolic and diastolic blood pressures of 16 to 19/9 to 11 mm Hg. The placebo corrected trough to peak ratio was evaluated in a study of candesartan cilexetil and hydrochlorothiazide 32 mg/12.5 mg and was 88%.</p>
<p> Most of the antihypertensive effect of the combination of candesartan cilexetil and hydrochlorothiazide was seen in 1 to 2 weeks with the full effect observed within 4 weeks. In long-term studies of up to one year, the blood pressure lowering effect of the combination was maintained. The antihypertensive effect was similar regardless of age or gender, and overall response to the combination was similar in black and non-black patients. No appreciable changes in heart rate were observed with combination therapy in controlled trials.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_5acab998-b4ab-415c-a003-b94c8ab34bcb"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. </p>
<p>Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). </p>
<p>Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but reductions in <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and cardiovascular mortality also have been seen regularly. </p>
<p>Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (for example, patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. </p>
<p>Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or diabetic kidney disease). These considerations may guide selection of therapy.</p>
<p>This fixed dose combination is not indicated for initial therapy (see <a href="#i4i_dosage_admin_id_2f004b2b-87aa-47c0-ab9c-9e657e0ceb4f">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_cd787d72-6c1e-48b5-9878-769cb7c05281"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Candesartan cilexetil and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to candesartan, to hydrochlorothiazide or to other sulfonamide-derived drugs.</p>
<p>Do not co-administer aliskiren with candesartan cilexetil and hydrochlorothiazide in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (see <a href="#ID_c0cba8f0-c709-4085-a951-f9e56631dde0">PRECAUTIONS: Drug Interactions</a>).</p>
<p>Candesartan cilexetil and hydrochlorothiazide is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_489f02d8-85ab-4a7f-bdb9-3af11eeac23d"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9dbf1829-b1ad-46a6-bce7-fad62a4a892a"></a><a name="section-5.1"></a><p></p>
<h2>Fetal Toxicity</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_28e2c9c5-53e1-400f-955a-891f1e8ea5f7"></a><a name="section-5.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Teratogenic Effects</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_aaae83ce-8a62-485d-8ea2-82193837a253"></a><a name="section-5.1.1.1"></a><p></p>
<h4>Pregnancy Category D</h4>
<p class="First">Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue candesartan cilexetil and hydrochlorothiazide as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy is important to optimize outcomes for both mother and fetus.</p>
<p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, discontinue candesartan cilexetil and hydrochlorothiazide, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of <span class="Italics">in utero</span> exposure to candesartan cilexetil and hydrochlorothiazide for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. (See <a href="#ID_f0846b0c-1dc2-406a-b6f5-a9354a37df1e">PRECAUTIONS, Pediatric Use</a>.)</p>
<p>There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or other adverse effects on embryo-fetal development when pregnant mice, rats or rabbits were treated orally with candesartan cilexetil alone or in combination with hydrochlorothiazide. For mice, the maximum dose of candesartan cilexetil was 1000 mg/kg/day (about 150 times the maximum recommended daily human dose [MRHD]<span class="Sup">1</span>). For rats, the maximum dose of candesartan cilexetil was 100 mg/kg/day (about 31 times the MRHD<span class="Sup">1</span>). For rabbits, the maximum dose of candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD<span class="Sup">1</span>). In each of these studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15 times the MRHD<span class="Sup">1</span> in mouse, rats, and rabbit, respectively). There was no evidence of harm to the rat or mouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant rat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.</p>
<p>Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in adults.</p>
<p>___________________</p>
<p><span class="Sup">1</span>Doses compared on the basis of body surface area. MRHD considered to be 32 mg for candesartan cilexetil and 12.5 mg for hydrochlorothiazide.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0b299c29-99b8-4a77-b9b3-b27d8f9811df"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">Candesartan cilexetil and hydrochlorothiazide can cause symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Patients with symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may require temporarily reducing the dose of candesartan cilexetil and hydrochlorothiazide or volume repletion. Volume and/or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span> should be corrected before initiating therapy with candesartan cilexetil and hydrochlorothiazide. </p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, candesartan cilexetil and hydrochlorothiazide may cause excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, which may lead to <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and (rarely) with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (see <a href="#ID_455153ec-5269-4412-9ac2-50236655089b">WARNINGS: <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a>). In such patients, candesartan cilexetil and hydrochlorothiazide therapy should be started under close medical supervision; they should be followed closely for the first 2 weeks of treatment and whenever the dose of candesartan or diuretic is increased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_455153ec-5269-4412-9ac2-50236655089b"></a><a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">Monitor renal function periodically in patients treated with candesartan cilexetil and hydrochlorothiazide. Changes in renal function including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">renal artery stenosis</span>, <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>, severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>) may be at particular risk of developing <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, or <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> on candesartan cilexetil and hydrochlorothiazide. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on candesartan cilexetil and hydrochlorothiazide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_95e9dd79-f8db-450f-a50f-636f89d24484"></a><a name="section-5.4"></a><p></p>
<h2>Potassium Abnormalities</h2>
<p class="First">Drugs that inhibit the renin-angiotensin system can cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Hydrochlorothiazide can cause <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. Hypomagnesema can result in <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> which appears difficult to treat despite potassium repletion. Monitor serum electrolytes periodically. </p>
<p>In clinical trials of various doses of candesartan cilexetil and hydrochlorothiazide, the incidence of hypertensive patients who developed <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (serum potassium &lt; 3.5 mEq/L) was 2.5% versus 2.1% for placebo; the incidence of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium &gt; 5.7 mEq/L) was 0.4% versus 1% for placebo. No patient receiving candesartan cilexetil and hydrochlorothiazide 16 mg/12.5 mg or 32 mg/12.5 mg was discontinued due to increases or decreases in serum potassium.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ea2e24e0-1a56-4885-bee5-9c157c851dfe"></a><a name="section-5.4.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span></span></h3>
<p class="First">Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Symptoms include acute onset of decreased visual acuity or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include a history of sulfonamide or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ee73a31e-23f0-4648-a91c-2bc4da63d873"></a><a name="section-5.4.2"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to hydrochlorothiazide may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, but are more likely in patients with such a history.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_260f13ea-ecd8-47ba-b13f-4238d30786c9"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_92ac0531-2b10-470e-abc5-5a8a4589dcf3"></a><a name="section-6.1"></a><p></p>
<h2>Metabolic Disturbances</h2>
<p class="First">Hydrochlorothiazide may alter glucose tolerance and raise serum levels of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides. </p>
<p>Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and precipitate <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> in susceptible patients. </p>
<p>Thiazides decrease urinary calcium excretion and may cause mild elevation of serum calcium. Avoid using candesartan cilexetil and hydrochlorothiazide in patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_13e1fb7d-a9cf-4ecd-a834-e70d5ae04bd6"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></h2>
<p class="First">Thiazide diuretics have been reported to cause exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_bef1ec11-b4d9-4bcf-859a-4c56ce17166f"></a><a name="section-6.3"></a><p></p>
<h2>Information for Patients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ab1c320c-7fcd-4e97-92f9-64837c4a8b6a"></a><a name="section-6.3.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Pregnancy</span></span></h3>
<p class="First">Female patients of childbearing age should be told about the consequences of exposure to candesartan cilexetil and hydrochlorothiazide during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_abb99c51-504f-4a46-917d-10c55e9806cb"></a><a name="section-6.3.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></span></h3>
<p class="First">Tell patients receiving candesartan cilexetil and hydrochlorothiazide that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. Tell patients that if <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, discontinue candesartan cilexetil and hydrochlorothiazide until the physician has been consulted.</p>
<p>Tell all patients that inadequate fluid intake, excessive perspiration, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> can lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>, with the same consequences of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and possible <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_47ef5afa-ff59-4e4a-b777-8e102bea6507"></a><a name="section-6.3.3"></a><p></p>
<h3><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></span></h3>
<p class="First">Tell patients receiving candesartan cilexetil and hydrochlorothiazide not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_c0cba8f0-c709-4085-a951-f9e56631dde0"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bd462867-bf7f-4108-9f0e-9d49f2f730d7"></a><a name="section-6.4.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Interactions Common to Both Candesartan Cilexetil and Hydrochlorothiazide</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6e807502-912e-4309-ade9-00a1953615c9"></a><a name="section-6.4.1.1"></a><p></p>
<h4>Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</h4>
<p class="First">In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including candesartan, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. These effects are usually reversible. Monitor renal function periodically in patients receiving candesartan and NSAID therapy. </p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including candesartan may be attenuated by NSAIDs including selective COX-2 inhibitors. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6b1397d2-dc9f-4ff1-b157-1ba0f7c2316e"></a><a name="section-6.4.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Lithium</span></span></h3>
<p class="First">Increases in serum lithium concentrations and <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> have been reported during concomitant administration of lithium with angiotensin II receptor antagonists or hydrochlorothiazide. Monitor serum lithium levels during concomitant use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_afd816e9-1e61-46b7-a1cd-f3841c444e4c"></a><a name="section-6.4.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Interactions with Candesartan Cilexetil</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7e73033c-3c3c-4ddb-abc8-47f37ed3e17c"></a><a name="section-6.4.3.1"></a><p></p>
<h4>Dual Blockade of the Renin-Angiotensin System (RAS)</h4>
<p class="First">Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and changes in renal function (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on candesartan cilexetil and hydrochlorothiazide and other agents that affect the RAS. </p>
<p>Do not co-administer aliskiren with candesartan cilexetil and hydrochlorothiazide in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Avoid use of aliskiren with candesartan cilexetil and hydrochlorothiazide in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt; 60 ml/min) (see <a href="#i4i_contraindications_id_cd787d72-6c1e-48b5-9878-769cb7c05281">CONTRAINDICATIONS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_39f74638-7c42-411d-8fb6-78ef050bc262"></a><a name="section-6.4.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Interactions with Hydrochlorothiazide</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a22ebc4b-01f6-47b1-a6b8-71499e42ed17"></a><a name="section-6.4.4.1"></a><p></p>
<h4>Alcohol, Barbiturates, or Narcotics</h4>
<p class="First">Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cd920a8c-9fde-4074-a9a6-a1a5947f0ae8"></a><a name="section-6.4.4.2"></a><p></p>
<h4>Antidiabetic Drugs (Oral Agents and Insulin)</h4>
<p class="First">Dosage adjustment of the antidiabetic drug may be required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5886b23b-19e0-4ccd-afac-6ea3e76fda4e"></a><a name="section-6.4.4.3"></a><p></p>
<h4>Ion Exchange Resins</h4>
<p class="First">Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. Stagger the dosage of hydrochlorothiazide and ion exchange resins such that hydrochlorothiazide is administered at least 4 hours before or 4 to 6 hours after the administration of resins.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3ca2aa58-c392-4674-8c64-e30c3e95249e"></a><a name="section-6.4.4.4"></a><p></p>
<h4>Skeletal Muscle Relaxants, Nondepolarizing (e.g., Tubocurarine)</h4>
<p class="First">Possible increased responsiveness to muscle relaxants such as curare derivatives.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e9160ea4-852f-4111-868f-3e1d5239d531"></a><a name="section-6.4.4.5"></a><p></p>
<h4>Digitalis</h4>
<p class="First">Thiazide-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> may predispose to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_9964d8a3-2028-4b7f-92b9-66a83c56a571"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity studies have been conducted with the combination of candesartan cilexetil and hydrochlorothiazide. There was no evidence of carcinogenicity when candesartan cilexetil was orally administered to mice and rats for up to 104 weeks at doses up to 100 and 1000 mg/kg/day, respectively. Rats received the drug by gavage whereas mice received the drug by dietary administration. These (maximally-tolerated) doses of candesartan cilexetil provided systemic exposures to candesartan (AUCs) that were, in mice, approximately 7 times and, in rats, more than 70 times the exposure in man at the maximum recommended daily human dose (32 mg). Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p> Candesartan cilexetil or candesartan (the active metabolite), in combination with hydrochlorothiazide, tested positive <span class="Italics">in vitro </span>in the Chinese hamster lung (CHL) chromosomal aberration assay and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mutagenicity assay. The candesartan cilexetil/hydrochlorothiazide combination tested negative for mutagenicity in bacteria (Ames test), for unscheduled DNA synthesis in rat liver, for chromosomal aberrations in rat bone marrow and for micronuclei in mouse bone marrow.</p>
<p> Both candesartan and its O-deethyl metabolite tested positive for genotoxicity in the <span class="Italics">in vitro </span>CHL chromosomal aberration assay. Neither compound tested positive in the Ames microbial mutagenesis assay or in the <span class="Italics">in vitro </span>mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell assay. Candesartan (but not its O-deethyl metabolite) was also evaluated <span class="Italics">in vivo </span>in the mouse micronucleus test and <span class="Italics">in vitro </span>in the Chinese hamster ovary (CHO) gene mutation assay, in both cases with negative results. Candesartan cilexetil was evaluated in the Ames test, the <span class="Italics">in vitro </span>mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell assay, the <span class="Italics">in vivo </span>rat hepatocyte unscheduled DNA synthesis assay and the <span class="Italics">in vivo </span>mouse micronucleus test, in each case with negative results. Candesartan cilexetil was not evaluated in the CHL chromosomal aberration or CHO gene mutation assays.</p>
<p> When hydrochlorothiazide was tested alone, positive results were obtained <span class="Italics">in vitro </span>in the CHO sister chromatid exchange (clastogenicity) and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (mutagenicity) assays and in the <span class="Italics">Aspergillus nidulans </span>non-disjunction assay. Hydrochlorothiazide was not genotoxic <span class="Italics">in vitro </span>in the Ames test for point mutations and the CHO test for chromosomal aberrations, or <span class="Italics">in vivo </span>in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene.</p>
<p> No fertility studies have been conducted with the combination of candesartan cilexetil and hydrochlorothiazide. Fertility and reproductive performance were not affected in studies with male and female rats given oral doses of up to 300 mg candesartan cilexetil/kg/day (83 times the maximum daily human dose of 32 mg on a body surface area basis). Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to conception and throughout gestation.</p>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_15e89010-d2ee-42d7-8b63-c00460bf99c4"></a><a name="section-6.5.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Nursing Mothers</span></span></h3>
<p class="First">It is not known whether candesartan is excreted in human milk, but candesartan has been shown to be present in rat milk. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_f0846b0c-1dc2-406a-b6f5-a9354a37df1e"></a><a name="section-6.5.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Pediatric Use</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4a08ef29-e42f-45a8-9a20-9cf321ee4f5d"></a><a name="section-6.5.2.1"></a><p></p>
<h4>Neonates with a History of In Utero Exposure to Candesartan Cilexetil and Hydrochlorothiazide</h4>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function.</p>
<p>Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_55036865-f64e-4f3d-952f-7f07a5e6101e"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bb0af525-54ce-4785-a50a-c853e7c8fc21"></a><a name="section-7.1"></a><p></p>
<h2>Candesartan Cilexetil and Hydrochlorothiazide</h2>
<p class="First">Candesartan cilexetil and hydrochlorothiazide has been evaluated for safety in more than 2,800 patients treated for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. More than 750 of these patients were studied for at least 6 months and more than 500 patients were treated for at least one year. Adverse experiences have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. The overall incidence of adverse events reported with candesartan cilexetil and hydrochlorothiazide was comparable to placebo. The overall frequency of adverse experiences was not related to dose, age, gender, or race.</p>
<p> In placebo-controlled trials that included 1,089 patients treated with various combinations of candesartan cilexetil (doses of 2 mg to 32 mg) and hydrochlorothiazide (doses of 6.25 mg to 25 mg) and 592 patients treated with placebo, adverse events, whether or not attributed to treatment, occurring in greater than 2% of patients treated with candesartan cilexetil and hydrochlorothiazide and that were more frequent for candesartan cilexetil and hydrochlorothiazide than placebo were: <span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorder</span>:</span></span> <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> (3.6% vs. 3%); <span class="Bold"><span class="Italics">Body as a Whole:</span></span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (3.3% vs. 2.4%); <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms (2.5% vs. 1.9%); <span class="Bold"><span class="Italics">Central/Peripheral Nervous System: </span></span><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2.9% vs. 1.2%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4f0bfd02-15e4-42e4-a3b3-af46445de21f"></a><a name="section-7.2"></a><p></p>
<h2>Post-Marketing Experience</h2>
<p class="First">The following have been very rarely reported in post-marketing experience with candesartan cilexetil:</p>
<p><span class="Bold"><span class="Italics">Digestive</span>: </span>Abnormal hepatic function and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p><span class="Bold"><span class="Italics">Hematologic</span>: </span><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p><span class="Bold"><span class="Italics">Immunologic: </span></span><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></p>
<p><span class="Bold"><span class="Italics">Metabolic and Nutritional Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span>: </span></span><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p>
<p><span class="Bold"><span class="Italics">Skin and Appendages Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p> Rare reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients receiving angiotensin II receptor blockers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_45125645-1173-4d86-967e-595cfc693463"></a><a name="section-7.3"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">Other adverse experiences that have been reported with hydrochlorothiazide, without regard to causality, are listed below:</p>
<p><span class="Bold"><span class="Italics">Gastrointestinal: </span></span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, cramping, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span></p>
<p><span class="Bold"><span class="Italics">Hematologic :</span></span><span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span></span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> </p>
<p><span class="Bold"><span class="Italics">Musculoskeletal: </span></span><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span></p>
<p><span class="Bold"><span class="Italics">Skin: </span></span><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span></p>
<p><span class="Bold"><span class="Italics">Special Senses: </span></span>transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span></p>
<p><span class="Bold"><span class="Italics">Urogenital: </span></span><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_88a18104-57e2-476e-87aa-9595058abe0a"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b30e522a-e8d1-468a-8ab4-f4dd74f090f4"></a><a name="section-8.1"></a><p></p>
<h2>Candesartan Cilexetil and Hydrochlorothiazide</h2>
<p class="First">No lethality was observed in acute toxicity studies in mice, rats and dogs given single oral doses of up to 2000 mg/kg of candesartan cilexetil or in rats given single oral doses of up to 2000 mg/kg of candesartan cilexetil in combination with 1000 mg/kg of hydrochlorothiazide. In mice given single oral doses of the primary metabolite, candesartan, the minimum lethal dose was greater than 1000 mg/kg but less than 2000 mg/kg.</p>
<p> Limited data are available in regard to overdosage with candesartan cilexetil in humans. The most likely manifestations of overdosage with candesartan cilexetil would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> could occur from parasympathetic (vagal) stimulation. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be initiated. For hydrochlorothiazide, the most common signs and symptoms observed are those caused by <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>) and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> resulting from excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. If digitalis has also been administered, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may accentuate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
<p> Candesartan cannot be removed by hemodialysis. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1f20ad5f-2840-42d1-9db8-695c3f74e53b"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Treatment</span></span></h3>
<p class="First">To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, consult your Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the <span class="Italics">Physicians’ Desk Reference (PDR)</span>. In managing <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, consider the possibilities of multiple-drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, drug-drug interactions, and altered pharmacokinetics in your patient.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_2f004b2b-87aa-47c0-ab9c-9e657e0ceb4f"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The usual recommended starting dose of candesartan cilexetil is 16 mg once daily when it is used as monotherapy in patients who are not volume depleted. Candesartan cilexetil tablets can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg. Patients requiring further reduction in blood pressure should be titrated to 32 mg. Doses larger than 32 mg do not appear to have a greater blood pressure lowering effect.</p>
<p> Hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg once daily.</p>
<p><span class="Bold"><span class="Italics">Use in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>Dosing recommendations for candesartan cilexetil and hydrochlorothiazide tablets in patients with creatinine clearance &lt; 30 mg/min cannot be provided (see <a href="#ID_39006eb7-c45c-461b-9367-ce4bb2f90ef6">SPECIAL POPULATIONS: <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a>).</p>
<p><span class="Bold"><span class="Italics">Use in Moderate to Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p>Candesartan cilexetil and hydrochlorothiazide tablets are not recommended for initiation because the appropriate starting dose, 8 mg, cannot be given (see <a href="#ID_38c7f1c2-354a-4c00-9e42-5d241d347fd0">SPECIAL POPULATIONS, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9a8e3a6b-74f4-4e64-96af-b45a24cd6b99"></a><a name="section-9.1"></a><p></p>
<h2>Replacement Therapy</h2>
<p class="First">The combination may be substituted for the titrated components.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3d9a3610-ad6f-4042-9f38-133310c88fc2"></a><a name="section-9.2"></a><p></p>
<h2>Dose Titration by Clinical Effect</h2>
<p class="First">A patient whose blood pressure is not controlled on 25 mg of hydrochlorothiazide once daily can expect an incremental effect from candesartan cilexetil and hydrochlorothiazide tablets 16 mg/12.5 mg. A patient whose blood pressure is controlled on 25 mg of hydrochlorothiazide but is experiencing decreases in serum potassium can expect the same or incremental blood pressure effects from candesartan cilexetil and hydrochlorothiazide tablets 16 mg/12.5 mg and serum potassium may improve.</p>
<p> A patient whose blood pressure is not controlled on 32 mg of candesartan cilexetil can expect incremental blood pressure effects from candesartan cilexetil and hydrochlorothiazide tablets 32 mg/12.5 mg and then 32 mg/25 mg. The maximal antihypertensive effect of any dose of candesartan cilexetil and hydrochlorothiazide tablets can be expected within 4 weeks of initiating that dose.</p>
<p>Candesartan cilexetil and hydrochlorothiazide tablets may be administered with other antihypertensive agents.</p>
<p>Candesartan cilexetil and hydrochlorothiazide tablets may be administered with or without food.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_d1b3d7a7-f8a7-48a5-bca9-8d7007fbab11"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Candesartan Cilexetil and Hydrochlorothiazide Tablets are available containing 16 mg or 32 mg of candesartan cilexetil, USP and 12.5 mg or 25 mg of hydrochlorothiazide, USP providing for the following available combinations: 16 mg/12.5 mg, 32 mg/12.5 mg or 32 mg/25 mg.</p>
<p>The 16 mg/12.5 mg tablets are peach, mottled, round, scored tablets debossed with <span class="Bold">M</span> on the left side of the score and <span class="Bold">X</span> on the right side of the score on one side of the tablet and <span class="Bold">C1 </span>on the other side of the tablet. They are available as follows:</p>
<p>NDC 0378-3001-77<br>bottles of 90 tablets</p>
<p>NDC 0378-3001-05<br>bottles of 500 tablets</p>
<p>The 32 mg/12.5 mg tablets are yellow, mottled, round, scored tablets debossed with <span class="Bold">M</span> on the left side of the score and <span class="Bold">X</span> on the right side of the score on one side of the tablet and <span class="Bold">C2 </span>on the other side of the tablet. They are available as follows:</p>
<p>NDC 0378-3002-77<br>bottles of 90 tablets</p>
<p>NDC 0378-3002-05<br>bottles of 500 tablets</p>
<p>The 32 mg/25 mg tablets are peach, mottled, round, scored tablets debossed with <span class="Bold">M </span>on the left of the score and<span class="Bold"> X</span> on the right of the score on one side of the tablet and <span class="Bold">C3</span> on the other side of the tablet. They are available as follows:</p>
<p>NDC 0378-3003-77<br>bottles of 90 tablets</p>
<p>NDC 0378-3003-05<br>bottles of 500 tablets</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep container tightly closed.</p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Manufactured in India by:<br><span class="Bold">Mylan Laboratories Limited</span><br>Hyderabad — 500 034, India<br>Code No.: MH/DRUGS/25/NKD/89</p>
<p>REVISED MARCH 2015<br>75056547<br>MX:CNDHTZ:R7</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_80ac6bf5-ebd7-4876-897b-7b5ce2838a4f"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 16 mg/12.5 mg</span></p>
<p><span class="Bold">NDC 0378-3001-77</span></p>
<p><span class="Bold">Candesartan </span><br><span class="Bold">Cilexetil and </span><br><span class="Bold">Hydrochlorothiazide </span><br><span class="Bold">Tablets </span><br><span class="Bold">16 mg/</span><br><span class="Bold">12.5 mg</span></p>
<p><span class="Bold">Rx only     90 Tablets</span></p>
<p>Each tablet contains:<br>Candesartan cilexetil, USP 16 mg<br>Hydrochlorothiazide, USP 12.5 mg</p>
<p><span class="Bold">Usual Adult Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Keep this and all medication out of the</span><br><span class="Bold">reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See <br>USP Controlled Room Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Made in India</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RMX3001MM3</span></p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Code No.: MH/DRUGS/25/NKD/89</p>
<div class="Figure">
<a name="id991295249"></a><img alt="Candesartan Cilexetil and Hydrochlorothiazide Tablets 16 mg/12.5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d&amp;name=image-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_203b6f9c-a38e-4cdd-a33f-c7cb5dd9dd8f"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 32 mg/12.5 mg</span></p>
<p><span class="Bold">NDC 0378-3002-77</span></p>
<p><span class="Bold">Candesartan</span><br><span class="Bold">Cilexetil and</span><br><span class="Bold">Hydrochlorothiazide</span><br><span class="Bold">Tablets</span><br><span class="Bold">32 mg/</span><br><span class="Bold">12.5 mg</span></p>
<p><span class="Bold">Rx only     90 Tablets</span></p>
<p>Each tablet contains:<br>Candesartan cilexetil, USP 32 mg<br>Hydrochlorothiazide, USP 12.5 mg</p>
<p><span class="Bold">Usual Adult Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Keep this and all medication out of the</span><br><span class="Bold">reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See <br>USP Controlled Room Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Made in India</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RMX3002MM3</span></p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Code No.: MH/DRUGS/25/NKD/89</p>
<div class="Figure">
<a name="id2143530198"></a><img alt="Candesartan Cilexetil and Hydrochlorothiazide Tablets 32 mg/12.5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d&amp;name=image-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2ed49c5f-eac8-4c84-a956-82efff1550fd"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 32 mg/25 mg</span></p>
<p><span class="Bold">NDC 0378-3003-77</span></p>
<p><span class="Bold">Candesartan</span><br><span class="Bold">Cilexetil and</span><br><span class="Bold">Hydrochlorothiazide</span><br><span class="Bold">Tablets</span><br><span class="Bold">32 mg/</span><br><span class="Bold">25 mg</span></p>
<p><span class="Bold">Rx only     90 Tablets</span></p>
<p>Each tablet contains:<br>Candesartan cilexetil, USP 32 mg<br>Hydrochlorothiazide, USP 25 mg</p>
<p><span class="Bold">Usual Adult Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Keep this and all medication out of the</span><br><span class="Bold">reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See <br>USP Controlled Room Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Made in India</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RMX3003MM3</span></p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Code No.: MH/DRUGS/25/NKD/89</p>
<div class="Figure">
<a name="id1465472575"></a><img alt="Candesartan Cilexetil and Hydrochlorothiazide Tablets 32 mg/25 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d&amp;name=image-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">candesartan cilexetil and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-3001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CANDESARTAN CILEXETIL</strong> (CANDESARTAN) </td>
<td class="formItem">CANDESARTAN CILEXETIL</td>
<td class="formItem">16 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;X;C1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-3001-77</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0378-3001-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090704</td>
<td class="formItem">12/04/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">candesartan cilexetil and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-3002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CANDESARTAN CILEXETIL</strong> (CANDESARTAN) </td>
<td class="formItem">CANDESARTAN CILEXETIL</td>
<td class="formItem">32 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;X;C2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-3002-77</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0378-3002-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090704</td>
<td class="formItem">12/04/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">candesartan cilexetil and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-3003</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CANDESARTAN CILEXETIL</strong> (CANDESARTAN) </td>
<td class="formItem">CANDESARTAN CILEXETIL</td>
<td class="formItem">32 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;X;C3</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-3003-77</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0378-3003-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090704</td>
<td class="formItem">12/04/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1aab4a2c-4c4f-494c-9f68-b303a84d933f</div>
<div>Set id: f3c4f7ed-e667-4528-a675-b032c2a4425d</div>
<div>Version: 8</div>
<div>Effective Time: 20150331</div>
</div>
</div> <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
